Monopar Therapeutics Inc.
MNPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $83 | $25 | $151 | $200 |
| - Cash | $46 | $7 | $8 | $20 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $38 | $17 | $143 | $180 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$16 | -$9 | -$11 | -$9 |
| % Margin | – | – | – | – |
| Net Income | -$16 | -$8 | -$11 | -$9 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.36 | -0.58 | -0.83 | -0.73 |
| % Growth | -134.5% | 30.1% | -13.7% | – |
| Operating Cash Flow | -$6 | -$8 | -$7 | -$7 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6 | -$8 | -$7 | -$7 |